Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 386

1.

FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.

Malka D, François E, Penault-Llorca F, Castan F, Bouché O, Bennouna J, Ghiringhelli F, Fouchardière C, Borg C, Samalin E, Bachet JB, Raoul JL, Miglianico L, Bengrine-Lefèvre L, Dahan L, Lecaille C, Aparicio T, Stanbury T, Perrier H, Cayre A, Laurent-Puig P, Gourgou S, Emile JF, Taïeb J.

Eur J Cancer. 2019 May 23;115:97-106. doi: 10.1016/j.ejca.2019.04.020. [Epub ahead of print]

PMID:
31129386
2.

Erdheim-Chester Disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1.

Razanamahery J, Diamond EL, Cohen-Aubart F, Plate KH, Lourida G, Charlotte F, Hélias-Rodzewicz Z, Goyal G, Go RS, Dogan A, Abdel-Wahab O, Durham B, Ozkaya N, Amoura Z, Emile JF, Haroche J.

Haematologica. 2019 May 23. pii: haematol.2019.216937. doi: 10.3324/haematol.2019.216937. [Epub ahead of print]

3.

Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.

Papo M, Cohen-Aubart F, Trefond L, Bauvois A, Amoura Z, Emile JF, Haroche J.

Curr Oncol Rep. 2019 May 21;21(7):62. doi: 10.1007/s11912-019-0810-6. Review.

PMID:
31115724
4.

Childhood pulmonary Langerhans cell histiocytosis: a comprehensive clinical-histopathological and BRAFV600E mutation study from the French national cohort.

Kambouchner M, Emile JF, Copin MC, Coulomb-Lherminé A, Sabourin JC, Valle VD, Sileo C, Le Pointe HD, Bégueret H, Galmiche L, Lambilliotte A, Paraf F, Piche M, Piguet C, Rullier A, Secq V, Serre I, Bernaudin JF, Donadieu J.

Hum Pathol. 2019 May 2. pii: S0046-8177(19)30070-X. doi: 10.1016/j.humpath.2019.04.005. [Epub ahead of print]

PMID:
31054893
5.

Sarcoidosis occurring during BRAF/MEK inhibitors is associated with paradoxical ERK activation in Erdheim-Chester patients.

Amoura A, Haroche J, Emile JF, Barete S, Helias-Rodzewicz Z, Charlotte F, Maisonobe T, Amoura Z, Cohen Aubart F.

J Eur Acad Dermatol Venereol. 2019 Apr 19. doi: 10.1111/jdv.15636. [Epub ahead of print] No abstract available.

PMID:
31002424
6.

Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors.

Roeser A, Cohen-Aubart F, Breillat P, Miyara M, Emile JF, Charlotte F, Donadieu J, Amoura Z, Haroche J.

Haematologica. 2019 Mar 28. pii: haematol.2018.214007. doi: 10.3324/haematol.2018.214007. [Epub ahead of print]

7.

Tubercular splenic abscesses: A rare entity sometimes hard to sterilize.

Matt M, Blot C, Thiry T, Antier A, Peschaud F, Roux AL, Emile JF, Davido B.

Int J Infect Dis. 2019 May;82:18-20. doi: 10.1016/j.ijid.2019.02.048. Epub 2019 Mar 5. No abstract available.

8.

Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study.

Perkins G, Svrcek M, Bouchet-Doumenq C, Voron T, Colussi O, Debove C, Merabtene F, Dumont S, Sauvanet A, Hammel P, Cros J, André T, Bachet JB, Bardier A, Douard R, Meatchi T, Peschaud F, Emile JF, Cojean-Zelek I, Laurent-Puig P, Taieb J.

Br J Cancer. 2019 Apr;120(7):697-702. doi: 10.1038/s41416-019-0415-8. Epub 2019 Mar 6.

PMID:
30837681
9.

Local immunomodulation combined to radiofrequency ablation results in a complete cure of local and distant colorectal carcinoma.

Lemdani K, Mignet N, Boudy V, Seguin J, Oujagir E, Bawa O, Peschaud F, Emile JF, Capron C, Malafosse R.

Oncoimmunology. 2019 Jan 10;8(3):1550342. doi: 10.1080/2162402X.2018.1550342. eCollection 2019.

10.

Human IFN-γ immunity to mycobacteria is governed by both IL-12 and IL-23.

Martínez-Barricarte R, Markle JG, Ma CS, Deenick EK, Ramírez-Alejo N, Mele F, Latorre D, Mahdaviani SA, Aytekin C, Mansouri D, Bryant VL, Jabot-Hanin F, Deswarte C, Nieto-Patlán A, Surace L, Kerner G, Itan Y, Jovic S, Avery DT, Wong N, Rao G, Patin E, Okada S, Bigio B, Boisson B, Rapaport F, Seeleuthner Y, Schmidt M, Ikinciogullari A, Dogu F, Tanir G, Tabarsi P, Bloursaz MR, Joseph JK, Heer A, Kong XF, Migaud M, Lazarov T, Geissmann F, Fleckenstein B, Arlehamn CL, Sette A, Puel A, Emile JF, van de Vosse E, Quintana-Murci L, Di Santo JP, Abel L, Boisson-Dupuis S, Bustamante J, Tangye SG, Sallusto F, Casanova JL.

Sci Immunol. 2018 Dec 21;3(30). pii: eaau6759. doi: 10.1126/sciimmunol.aau6759.

PMID:
30578351
11.

Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study.

Héritier S, Barkaoui MA, Miron J, Thomas C, Moshous D, Lambilliotte A, Mazingue F, Kebaili K, Jeziorski E, Plat G, Aladjidi N, Pacquement H, Galambrun C, Brugières L, Leverger G, Mansuy L, Paillard C, Deville A, Pagnier A, Lutun A, Gillibert-Yvert M, Stephan JL, Cohen-Aubart F, Haroche J, Pellier I, Millot F, Gandemer V, Martin-Duverneuil N, Taly V, Hélias-Rodzewicz Z, Emile JF, Hoang-Xuan K, Idbaih A, Donadieu J.

Br J Haematol. 2018 Nov;183(4):608-617. doi: 10.1111/bjh.15577. Epub 2018 Nov 12.

PMID:
30421536
12.

Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial.

Bennouna J, André T, Campion L, Hiret S, Miglianico L, Mineur L, Touchefeu Y, Artru P, Asmis T, Bouché O, Borde F, Kavan P, Lam YH, Rajpar LS, Emile JF, Jouffroy C, Gill S, Taïeb J.

Clin Colorectal Cancer. 2019 Mar;18(1):e69-e73. doi: 10.1016/j.clcc.2018.09.011. Epub 2018 Oct 19.

PMID:
30415988
13.

Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer.

Weinstein AM, Giraldo NA, Petitprez F, Julie C, Lacroix L, Peschaud F, Emile JF, Marisa L, Fridman WH, Storkus WJ, Sautès-Fridman C.

Cancer Immunol Immunother. 2019 Jan;68(1):109-120. doi: 10.1007/s00262-018-2259-0. Epub 2018 Oct 12.

PMID:
30315348
14.

Contribution of genetic amplification by PCR for the diagnosis of Helicobacter pylori infection in patients receiving proton pump inhibitors.

Bazin T, Nchare Mfondi A, Julie C, Émile JF, Raymond J, Lamarque D.

United European Gastroenterol J. 2018 Oct;6(8):1267-1273. doi: 10.1177/2050640618787055. Epub 2018 Jun 27.

15.

A case of Erdheim-Chester disease with spinal cord compression and sphenoid sinus involvement.

Bunaux K, Sevestre H, Emile JF, Capel C, Chenin L, Peltier J.

Neurochirurgie. 2018 Dec;64(6):439-441. doi: 10.1016/j.neuchi.2018.08.002. Epub 2018 Sep 28.

PMID:
30274919
16.

Highly sensitive methods are required to detect mutations in histiocytoses.

Melloul S, Hélias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Fraitag S, Terrones N, Riller Q, Chazal T, Héritier S, Moreau A, Kambouchner M, Copin MC, Donadieu J, Taly V, Amoura Z, Haroche J, Emile JF.

Haematologica. 2019 Mar;104(3):e97-e99. doi: 10.3324/haematol.2018.201194. Epub 2018 Sep 27. No abstract available.

17.

Langerhans Cell Histiocytoma: A Benign Histiocytic Neoplasm of Diverse Lines of Terminal Differentiation.

Dupeux M, Boccara O, Frassati-Biaggi A, Hélias-Rodzewicz Z, Leclerc-Mercier S, Bodemer C, Molina TJ, Emile JF, Fraitag S.

Am J Dermatopathol. 2019 Jan;41(1):29-36. doi: 10.1097/DAD.0000000000001255. Review.

PMID:
30252693
18.

Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab.

Costantini A, Julie C, Dumenil C, Hélias-Rodzewicz Z, Tisserand J, Dumoulin J, Giraud V, Labrune S, Chinet T, Emile JF, Giroux Leprieur E.

Oncoimmunology. 2018 Apr 20;7(8):e1452581. doi: 10.1080/2162402X.2018.1452581. eCollection 2018.

19.

Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment.

Franconieri F, Deshayes S, de Boysson H, Trad S, Martin Silva N, Terrier B, Bienvenu B, Galateau-Sallé F, Emile JF, Johnson AC, Aouba A.

Oncoimmunology. 2018 Apr 9;7(8):e1450712. doi: 10.1080/2162402X.2018.1450712. eCollection 2018.

20.

CDKN2A Depletion Causes Aneuploidy and Enhances Cell Proliferation in Non-Immortalized Normal Human Cells.

Hélias-Rodzewicz Z, Lourenco N, Bakari M, Capron C, Emile JF.

Cancer Invest. 2018;36(6):338-348. doi: 10.1080/07357907.2018.1491588. Epub 2018 Aug 23.

PMID:
30136875
21.

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.

Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, Piñeyro D, Sanchez-Cespedes M, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin MC, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga LM, Gil-Bazo I, Baraibar I, Lozano MD, Varela M, Ruffinelli JC, Palmero R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó C, Vilariño N, Prat A, Reguart N, Benito A, Garrido P, Barragan I, Emile JF, Rosell R, Brambilla E, Esteller M.

Lancet Respir Med. 2018 Oct;6(10):771-781. doi: 10.1016/S2213-2600(18)30284-4. Epub 2018 Aug 9.

22.

Hypoalphalipoproteinemia and BRAFV600E Mutation Are Major Predictors of Aortic Infiltration in the Erdheim-Chester Disease.

Cohen-Aubart F, Guerin M, Poupel L, Cluzel P, Saint-Charles F, Charlotte F, Arsafi Y, Emile JF, Frisdal E, Le Goff C, Donadieu J, Amoura Z, Lesnik P, Haroche J, Le Goff W.

Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1913-1925. doi: 10.1161/ATVBAHA.118.310803.

PMID:
29930009
23.

Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.

Gallois C, Taieb J, Le Corre D, Le Malicot K, Tabernero J, Mulot C, Seitz JF, Aparicio T, Folprecht G, Lepage C, Mini E, Van Laethem JL, Emile JF, Laurent-Puig P; PETACC8 investigators.

Clin Cancer Res. 2018 Oct 1;24(19):4745-4753. doi: 10.1158/1078-0432.CCR-18-0866. Epub 2018 Jun 19.

PMID:
29921730
24.

BRAF V600E mutation detected in a case of Rosai-Dorfman disease.

Fatobene G, Haroche J, Hélias-Rodzwicz Z, Charlotte F, Taly V, Ferreira AM, Abdo ANR, Rocha V, Emile JF.

Haematologica. 2018 Aug;103(8):e377-e379. doi: 10.3324/haematol.2018.190934. Epub 2018 May 10. No abstract available.

25.

Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer.

Giroux Leprieur E, Herbretau G, Dumenil C, Julie C, Giraud V, Labrune S, Dumoulin J, Tisserand J, Emile JF, Blons H, Chinet T.

Oncoimmunology. 2018 Jan 29;7(5):e1424675. doi: 10.1080/2162402X.2018.1424675. eCollection 2018.

26.

Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease.

Abla O, Jacobsen E, Picarsic J, Krenova Z, Jaffe R, Emile JF, Durham BH, Braier J, Charlotte F, Donadieu J, Cohen-Aubart F, Rodriguez-Galindo C, Allen C, Whitlock JA, Weitzman S, McClain KL, Haroche J, Diamond EL.

Blood. 2018 Jun 28;131(26):2877-2890. doi: 10.1182/blood-2018-03-839753. Epub 2018 May 2. Review.

PMID:
29720485
27.

Rotation of a floating hydrophobic disk: influence of line tension.

Emile J, Tabuteau H, Emile O.

Soft Matter. 2018 May 16;14(19):3829-3833. doi: 10.1039/c8sm00309b.

PMID:
29718056
28.

[Rosai-Dorfman disease: Diagnosis and therapeutic challenges].

Cohen Aubart F, Haroche J, Emile JF, Charlotte F, Barete S, Schleinitz N, Donadieu J, Amoura Z.

Rev Med Interne. 2018 Aug;39(8):635-640. doi: 10.1016/j.revmed.2018.02.011. Epub 2018 Mar 1. Review. French.

PMID:
29501513
29.

Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies.

Cabannes-Hamy A, Peyrade F, Jardin F, Emile JF, Delwail V, Mounier N, Haioun C, Perrot A, Fitoussi O, Lara D, Delarue R, André M, Offner F, Ghesquières H, Pascal L, Soussain C, Lazarovici J, Schiano JM, Gaulard P, Tilly H, Thieblemont C; LYSA; lymphoma study association.

Cancer Med. 2018 Mar;7(3):539-548. doi: 10.1002/cam4.1139. Epub 2018 Feb 23.

30.

Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort.

Cohen-Aubart F, Emile JF, Carrat F, Helias-Rodzewicz Z, Taly V, Charlotte F, Cluzel P, Donadieu J, Idbaih A, Barete S, Amoura Z, Haroche J.

Am J Hematol. 2018 May;93(5):E114-E117. doi: 10.1002/ajh.25055. Epub 2018 Feb 10. No abstract available.

31.

Efficacy of infliximab in the treatment of Erdheim-Chester disease.

Cohen-Aubart F, Maksud P, Emile JF, Benameur N, Charlotte F, Cluzel P, Amoura Z, Haroche J.

Ann Rheum Dis. 2018 Sep;77(9):1387-1390. doi: 10.1136/annrheumdis-2017-212678. Epub 2018 Jan 23. No abstract available.

PMID:
29363511
32.

Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration.

Wang L, Dumenil C, Julié C, Giraud V, Dumoulin J, Labrune S, Chinet T, Emile JF, He B, Giroux Leprieur E.

Oncotarget. 2017 Nov 23;8(65):109818-109835. doi: 10.18632/oncotarget.22651. eCollection 2017 Dec 12. Review.

33.

Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.

Taieb J, Kourie HR, Emile JF, Le Malicot K, Balogoun R, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Mulot C, Bouché O, Aparicio T, Michel P, Thaler J, Bridgewater J, Van Cutsem E, Perkins G, Lepage C, Salazar R, Laurent-Puig P; Pan-European Trials in Alimentary Tract Cancer (PETACC)-8 Investigators.

JAMA Oncol. 2018 Jul 12;4(7):e173695. doi: 10.1001/jamaoncol.2017.3695. Epub 2018 Jul 12.

34.

Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Lupinacci RM, Goloudina A, Buhard O, Bachet JB, Maréchal R, Demetter P, Cros J, Bardier-Dupas A, Collura A, Cervera P, Scriva A, Dumont S, Hammel P, Sauvanet A, Louvet C, Delpéro JR, Paye F, Vaillant JC, André T, Closset J, Emile JF, Van Laethem JL, Jonchère V, Abd Alsamad I, Antoine M, Rodenas A, Fléjou JF, Dusetti N, Iovanna J, Duval A, Svrcek M.

Gastroenterology. 2018 Mar;154(4):1061-1065. doi: 10.1053/j.gastro.2017.11.009. Epub 2017 Nov 20.

PMID:
29158190
35.

Neurodegeneration in histiocytoses might start in utero.

Haroche J, Cohen-Aubart F, Emile JF, Donadieu J, Amoura Z.

Lancet Neurol. 2017 Dec;16(12):953-954. doi: 10.1016/S1474-4422(17)30373-3. Epub 2017 Oct 27. No abstract available.

PMID:
29111143
36.

FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study.

Casasnovas RO, Ysebaert L, Thieblemont C, Bachy E, Feugier P, Delmer A, Tricot S, Gabarre J, Andre M, Fruchart C, Mounier N, Delarue R, Meignan M, Berriolo-Riedinger A, Bardet S, Emile JF, Jais JP, Haioun C, Tilly H, Morschhauser F.

Blood. 2017 Sep 14;130(11):1315-1326. doi: 10.1182/blood-2017-02-766691. Epub 2017 Jul 12.

37.

High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis.

Papo M, Diamond EL, Cohen-Aubart F, Emile JF, Roos-Weil D, Gupta N, Durham BH, Ozkaya N, Dogan A, Ulaner GA, Rampal R, Kahn JE, Sené T, Charlotte F, Hervier B, Besnard C, Bernard OA, Settegrana C, Droin N, Hélias-Rodzewicz Z, Amoura Z, Abdel-Wahab O, Haroche J.

Blood. 2017 Aug 24;130(8):1007-1013. doi: 10.1182/blood-2017-01-761718. Epub 2017 Jul 5.

38.

New somatic BRAF splicing mutation in Langerhans cell histiocytosis.

Héritier S, Hélias-Rodzewicz Z, Chakraborty R, Sengal AG, Bellanné-Chantelot C, Thomas C, Moreau A, Fraitag S, Allen CE, Donadieu J, Emile JF.

Mol Cancer. 2017 Jul 6;16(1):115. doi: 10.1186/s12943-017-0690-z.

39.

Variation of mutant allele frequency in NRAS Q61 mutated melanomas.

Hélias-Rodzewicz Z, Funck-Brentano E, Terrones N, Beauchet A, Zimmermann U, Marin C, Saiag P, Emile JF.

BMC Dermatol. 2017 Jul 1;17(1):9. doi: 10.1186/s12895-017-0061-x.

40.

Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study).

Cohen Aubart F, Emile JF, Carrat F, Charlotte F, Benameur N, Donadieu J, Maksud P, Idbaih A, Barete S, Hoang-Xuan K, Amoura Z, Haroche J.

Blood. 2017 Sep 14;130(11):1377-1380. doi: 10.1182/blood-2017-03-771873. Epub 2017 Jun 30. No abstract available.

41.

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

Emile JF, Julié C, Le Malicot K, Lepage C, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Dimet S, Boulagnon-Rombi C, Allard MA, Penault-Llorca F, Bennouna J, Laurent-Puig P, Taieb J; PETACC8 Study Investigators; Austrian Breast and Colorectal cancer Study Group (ABCSG); Belgian Group of Digestive Oncology (BGDO); Lone Nørgård Petersen; Fédération Francophone de Cancérologie Digestive (FFCD); Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER); Fédération Nationale des Centres de Lutte Contre le Cancer Association Européenne de Recherche en Oncologie (AERO); Arbeitsgemeinschaft Internistische Onkologie (AIO); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico dell'Italia Meridionale (GOIM); Istituto Oncologico Romagnolo (IOR); Gruppo Cooperativo Chirurgico Italiano (GOCCI); Gruppo Oncologico Nord Ovest (GONO); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC); Gruppo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação Oncológica (GCCD, APIO); Grupo Español para el Tratamiento de los Tumores Digestivos (TTD); John Allen Bridgewater.

Eur J Cancer. 2017 Sep;82:16-24. doi: 10.1016/j.ejca.2017.04.025. Epub 2017 Jun 23.

PMID:
28651158
42.

Reply to "Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma" by Mesbah Ardakani et al.

Boespflug A, Funck-Brentano E, Hélias-Rodzewicz Z, Maucort-Boulch D, Beauchet A, Bringuier PP, Dumontet C, Emile JF, Saiag P, Dalle S.

Pigment Cell Melanoma Res. 2017 Sep;30(5):498-500. doi: 10.1111/pcmr.12606. Epub 2017 Jul 23. No abstract available.

PMID:
28627072
43.

Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells.

Durham BH, Roos-Weil D, Baillou C, Cohen-Aubart F, Yoshimi A, Miyara M, Papo M, Hélias-Rodzewicz Z, Terrones N, Ozkaya N, Dogan A, Rampal R, Urbain F, Le Fèvre L, Diamond EL, Park CY, Papo T, Charlotte F, Gorochov G, Taly V, Bernard OA, Amoura Z, Abdel-Wahab O, Lemoine FM, Haroche J, Emile JF.

Blood. 2017 Jul 13;130(2):176-180. doi: 10.1182/blood-2016-12-757377. Epub 2017 May 31.

44.

Circulating cell-free BRAFV600E as a biomarker in children with Langerhans cell histiocytosis.

Héritier S, Hélias-Rodzewicz Z, Lapillonne H, Terrones N, Garrigou S, Normand C, Barkaoui MA, Miron J, Plat G, Aladjidi N, Pagnier A, Deville A, Gillibert-Yvert M, Moshous D, Lefèvre-Utile A, Lutun A, Paillard C, Thomas C, Jeziorski E, Nizard P, Taly V, Emile JF, Donadieu J.

Br J Haematol. 2017 Aug;178(3):457-467. doi: 10.1111/bjh.14695. Epub 2017 Apr 25.

PMID:
28444728
45.

Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.

Del Rio M, Mollevi C, Bibeau F, Vie N, Selves J, Emile JF, Roger P, Gongora C, Robert J, Tubiana-Mathieu N, Ychou M, Martineau P.

Eur J Cancer. 2017 May;76:68-75. doi: 10.1016/j.ejca.2017.02.003. Epub 2017 Mar 8.

PMID:
28284171
46.

Histiocytoses: emerging neoplasia behind inflammation.

Haroche J, Cohen-Aubart F, Rollins BJ, Donadieu J, Charlotte F, Idbaih A, Vaglio A, Abdel-Wahab O, Emile JF, Amoura Z.

Lancet Oncol. 2017 Feb;18(2):e113-e125. doi: 10.1016/S1470-2045(17)30031-1. Review.

PMID:
28214412
47.

NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.

Rusakiewicz S, Perier A, Semeraro M, Pitt JM, Pogge von Strandmann E, Reiners KS, Aspeslagh S, Pipéroglou C, Vély F, Ivagnes A, Jegou S, Halama N, Chaigneau L, Validire P, Christidis C, Perniceni T, Landi B, Berger A, Isambert N, Domont J, Bonvalot S, Terrier P, Adam J, Coindre JM, Emile JF, Poirier-Colame V, Chaba K, Rocha B, Caignard A, Toubert A, Enot D, Koch J, Marabelle A, Lambert M, Caillat-Zucman S, Leyvraz S, Auclair C, Vivier E, Eggermont A, Borg C, Blay JY, Le Cesne A, Mir O, Zitvogel L.

Oncoimmunology. 2016 Apr 25;6(1):e1137418. doi: 10.1080/2162402X.2015.1137418. eCollection 2017.

48.

Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas.

Pilati C, Shinde J, Alexandrov LB, Assié G, André T, Hélias-Rodzewicz Z, Ducoudray R, Le Corre D, Zucman-Rossi J, Emile JF, Bertherat J, Letouzé E, Laurent-Puig P.

J Pathol. 2017 May;242(1):10-15. doi: 10.1002/path.4880. Epub 2017 Mar 29.

PMID:
28127763
49.

French updated recommendations in Stage I to III melanoma treatment and management.

Guillot B, Dalac S, Denis MG, Dupuy A, Emile JF, De La Fouchardiere A, Hindie E, Jouary T, Lassau N, Mirabel X, Piperno Neumann S, De Raucourt S, Vanwijck R.

J Eur Acad Dermatol Venereol. 2017 Apr;31(4):594-602. doi: 10.1111/jdv.14064. Epub 2017 Jan 24.

PMID:
28120528
50.

Somatic mutational spectrum analysis in a prospective series of 104 gastrointestinal stromal tumors.

Guenat D, Deroo O, Magnin S, Chaigneau L, Monnien F, Borg C, Mougin C, Emile JF, Prétet JL.

Oncol Rep. 2017 Mar;37(3):1671-1681. doi: 10.3892/or.2017.5384. Epub 2017 Jan 17.

PMID:
28098915

Supplemental Content

Support Center